Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study

NCT02678299 is registered in ClinicalTrials.gov with University of Aarhus as lead sponsor.

NCT NCT02678299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02678299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
Lead sponsor
University of Aarhus
Phase
Phase 1/2
Overall status
Unknown status
Start date
February 29, 2016
Completion date
December 31, 2025
Enrollment
60 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

malignant lymphoma